recombinant streptokinase
Phase 2- Indications
- Myocardial infarction, Ischemic stroke
Company intelligence / Profile preview
Epygen Labs/Epygen Biotech develops and manufactures recombinant therapeutic proteins targeting oncology, cardiovascular disease, immune disorders, and vaccines. It also produces a wide range of specialty enzymes for industrial applications including oil & gas recovery, pulp & paper processing, textiles/leather treatment, detergents/home care products. The company leverages expertise in recombinant protein expression/purification to provide affordable biologics regionally. Its pipeline includes both marketed industrial enzyme products and early-stage/preclinical biotherapeutic candidates.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Epygen Labs.